Drs Data&Rsrch (DRS) 시세

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) announces that Alliance Global Partners (AGP) has issued an analyst coverage research report on the Company’s common...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

- Preliminary Analysis confirms the presence of TGR-63 in brain tissue and shows no adverse effects. - IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced preclinical...

Form DEF 14A - Other definitive proxy statements

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

- Mouse Studies Demonstrate Significant Reduction in Amyloid Plaque: 78% in Cortex and 85% in Hippocampus - IGC Pharma, Inc. (NYSE American: IGC) ("IGC" or the "Company") today announced...

IGC Reports Financial Results for Fiscal Year Ended March 31, 2024

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, has announced its financial results for the fiscal year ended March 31, 2024 (“Fiscal...

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside chat hosted by Ascendiant Capital...

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

-- Study Deepens Understanding of Treatments for Alzheimer’s Patients, Enabling More Effective Treatments -- IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced the...

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

-- Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's -- IGC Pharma, Inc (NYSE American: IGC) ("IGC" or the "Company"), today announced patient enrollment at...

Form SC 13D - General statement of acquisition of beneficial ownership